Published in Cancer Weekly, November 16th, 2004
Additionally, in all patients, 64% of patients in the REMICADE treated groups experienced no worsening in joint erosion scores compared with 49% of patients receiving methotrexate alone. These new findings emerged from the ASPIRE...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.